佰金生命科学(01466)预期年度亏损同比减少

智通财经
Jul 24

智通财经APP讯,佰金生命科学(01466)发布公告,本集团预期截至2025年3月31日止年度将取得亏损约10万港元,而截至2024年3月31日止年度则取得亏损约为850万港元。

亏损大幅减少主要由于下列因素:收益及毛利增长,主要来自珠宝业务分部; 应收货款及其他应收账款的预期信贷亏损拨备拨回净额增加;其他收益净额增加;及经抵销商誉减值亏损及行政开支增加。

此外,继续停牌。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10